AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 34120214 — intervention group
Group type: EXPERIMENTAL
Intervention: Autologous antigen-specific T-cells (Melan-A and MELOE-1)
Number of subjects: 6
Study 34120229 — intervention group
Group type: EXPERIMENTAL
Intervention: GRASP dynamic contrast-enhanced (DCE)-MRI
Number of subjects: 64
Study 34120312 — intervention group
Group type: EXPERIMENTAL
Intervention: Dacomitinib 45 mg QD
Number of subjects: 452
Study 34120312 — intervention group
Group type: EXPERIMENTAL
Intervention: Gefitinib 250 mg QD
Number of subjects: 452
Study 34120312 — intervention group
Group type: COMPARATOR
Intervention: PPI use
Number of subjects: 452
Study 34120316 — intervention group
Group type: EXPERIMENTAL
Intervention: PNplus Panel
Number of subjects: 90
Study 34120316 — intervention group
Group type: COMPARATOR
Intervention: Conventional microbiology
Number of subjects: 90
Study 34120773 — intervention group
Group type: EXPERIMENTAL
Intervention: Dasatinib 140 mg once daily
Number of subjects: 0
Study 34120773 — intervention group
Group type: COMPARATOR
Intervention: Dasatinib 100 mg once daily
Number of subjects: 0
Study 34122314 — intervention group
Group type: EXPERIMENTAL
Intervention: Heart Rate Variability Biofeedback
Number of subjects: 0
Study 34122314 — intervention group
Group type: COMPARATOR
Intervention: Sham Control
Number of subjects: 0
Study 34122611 — intervention group
Group type: EXPERIMENTAL
Intervention: Traditional Chinese Medicine
Number of subjects: 0
Study 34122611 — intervention group
Group type: COMPARATOR
Intervention: Not available
Number of subjects: 0
Study 34123791 — intervention group
Group type: EXPERIMENTAL
Intervention: Nilotinib 300 mg twice-daily
Number of subjects: 0
Study 34123791 — intervention group
Group type: EXPERIMENTAL
Intervention: Treatment-free remission (TFR)
Number of subjects: 0
Study 34123791 — intervention group
Group type: COMPARATOR
Intervention: Nilotinib
Number of subjects: 0
Study 34123956 — intervention group
Group type: EXPERIMENTAL
Intervention: National School-Based Health Lifestyles Intervention
Number of subjects: 0
Study 34123963 — intervention group
Group type: EXPERIMENTAL
Intervention: Telehealth Delivered Rehabilitative Exercise (MSTEP)
Number of subjects: 0
Study 34124106 — intervention group
Group type: EXPERIMENTAL
Intervention: Sleep-disordered breathing treatment, specific intervention details not available
Number of subjects: 0
Study 34124111 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Controlled Intravenous Analgesia with Tramadol
Number of subjects: 0
Study 34124111 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34124781 — intervention group
Group type: EXPERIMENTAL
Intervention: Nephrotoxic serum (NTS) administered on day 14 after EAV induction.
Number of subjects: 0
Study 34124781 — intervention group
Group type: EXPERIMENTAL
Intervention: Small molecule kinase inhibitor (fostamatinib) administered over a 4-day treatment period.
Number of subjects: 0
Study 34124781 — intervention group
Group type: COMPARATOR
Intervention: Control protein (not MPO) administered instead of MPO.
Number of subjects: 0
Study 34124781 — intervention group
Group type: COMPARATOR
Intervention: Sub-nephritogenic NTS alone.
Number of subjects: 0
Study 34124920 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down guidance with specific target template (picture cue)
Number of subjects: 2
Study 34124920 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-down guidance with semantic consistency (consistent vs. inconsistent)
Number of subjects: 2
Study 34124920 — intervention group
Group type: EXPERIMENTAL
Intervention: Bottom-up guidance with high salience targets
Number of subjects: 2
Study 34124920 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional capture by distractors (picture cue)
Number of subjects: 2
Study 34124920 — intervention group
Group type: EXPERIMENTAL
Intervention: Attentional capture by distractors (all conditions)
Number of subjects: 2
Study 34125075 — intervention group
Group type: COMPARATOR
Intervention: Best-practice condition (SMS notifications and survey)
Number of subjects: 0
Study 34125075 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile 360° videos (combined with best-practice condition)
Number of subjects: 0
Study 34125075 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation and Problem Solving (MAPS) coaching (combined with best-practice condition)
Number of subjects: 0
Study 34125075 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile 360° videos
Number of subjects: 0
Study 34125075 — intervention group
Group type: EXPERIMENTAL
Intervention: MAPS coaching
Number of subjects: 0
Study 34125405 — intervention group
Group type: EXPERIMENTAL
Intervention: Glecaprevir/pibrentasvir (8-week treatment)
Number of subjects: 2036
Study 34125421 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisocabtagene maraleucel (liso-cel)
Number of subjects: 261
Study 34125951 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravesical gemcitabine
Number of subjects: 1222
Study 34125951 — intervention group
Group type: COMPARATOR
Intervention: Saline
Number of subjects: 1222
Study 34125952 — intervention group
Group type: EXPERIMENTAL
Intervention: Endovascular thrombectomy plus medical treatment
Number of subjects: 3793
Study 34126109 — intervention group
Group type: EXPERIMENTAL
Intervention: ALXN1830 (10 mg/kg) administered as five weekly intravenous doses
Number of subjects: 8
Study 34126262 — intervention group
Group type: EXPERIMENTAL
Intervention: PF-06480605 (500 mg intravenous every 2 weeks, 7 doses total)
Number of subjects: 50
Study 34126278 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone, Azithromycin, and Montelukast (FAM) treatment
Number of subjects: 33
Study 34126278 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-BOS chronic GVHD, N=31)
Number of subjects: 33
Study 34126278 — intervention group
Group type: COMPARATOR
Intervention: Control group (no chronic GVHD, N=29)
Number of subjects: 33
Study 34126756 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardioprotective medications
Number of subjects: 61
Study 34126756 — intervention group
Group type: EXPERIMENTAL
Intervention: Normal myocardium (%) derived by fast-strain-encoded cardiovascular magnetic resonance
Number of subjects: 61
Study 34126756 — intervention group
Group type: COMPARATOR
Intervention: No intervention
Number of subjects: 61
Study 34126876 — intervention group
Group type: EXPERIMENTAL
Intervention: Cochlear Implantation (CI)
Number of subjects: 0
Study 34126876 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34126939 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF (25 mg/d)
Number of subjects: 40
Study 34126939 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF (300 mg/d)
Number of subjects: 40
Study 34126939 — intervention group
Group type: EXPERIMENTAL
Intervention: ETV (0.5 mg/d)
Number of subjects: 40
Study 34126939 — intervention group
Group type: COMPARATOR
Intervention: TAF, TDF, ETV
Number of subjects: 40
Study 34126939 — intervention group
Group type: EXPERIMENTAL
Intervention: TAF
Number of subjects: 40
Study 34126939 — intervention group
Group type: EXPERIMENTAL
Intervention: TDF
Number of subjects: 40
Study 34126944 — intervention group
Group type: EXPERIMENTAL
Intervention: Cerebrovascular pathology
Number of subjects: 410
Study 34126944 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed pathology
Number of subjects: 410
Study 34126944 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurodegeneration
Number of subjects: 410
Study 34126944 — intervention group
Group type: EXPERIMENTAL
Intervention: Pathological MRI markers (MTA and lacunes)
Number of subjects: 410
Study 34126944 — intervention group
Group type: EXPERIMENTAL
Intervention: History of clinical stroke prior to the index stroke
Number of subjects: 410
Study 34126944 — intervention group
Group type: EXPERIMENTAL
Intervention: PCI for women
Number of subjects: 410
Study 34126949 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon cancer surgery
Number of subjects: 0
Study 34127247 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate improvement in left ventricular ejection fraction (LVEF) defined as an absolute increase of ≥5% in LVEF at post-procedure echocardiogram.
Number of subjects: 694
Study 34127247 — intervention group
Group type: COMPARATOR
Intervention: No immediate improvement in left ventricular ejection fraction (LVEF).
Number of subjects: 694
Study 34127618 — intervention group
Group type: EXPERIMENTAL
Intervention: Management strategies for post-PE syndrome
Number of subjects: 0
Study 34127618 — intervention group
Group type: EXPERIMENTAL
Intervention: Evaluation and treatment for chronic thromboembolic pulmonary hypertension (CTEPH)
Number of subjects: 0
Study 34127618 — intervention group
Group type: EXPERIMENTAL
Intervention: Active studies designed to optimize management of post-PE syndrome
Number of subjects: 0
Study 34127633 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity cycling (1 h at 65% peak aerobic capacity)
Number of subjects: 15
Study 34128387 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 34128409 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Coll2-1
Number of subjects: 121
Study 34128409 — intervention group
Group type: EXPERIMENTAL
Intervention: Serum Coll2-1NO2
Number of subjects: 121
Study 34128464 — intervention group
Group type: EXPERIMENTAL
Intervention: Primacy model
Number of subjects: 0
Study 34128464 — intervention group
Group type: EXPERIMENTAL
Intervention: Neural encoding of the Primacy model
Number of subjects: 0
Study 34128464 — intervention group
Group type: COMPARATOR
Intervention: Alternative temporal representations
Number of subjects: 0
Study 34128558 — intervention group
Group type: EXPERIMENTAL
Intervention: ImmunoCAP™ sx1 and fx5 mixes
Number of subjects: 106
Study 34128558 — intervention group
Group type: EXPERIMENTAL
Intervention: ImmunoCAP ISAC™ 112 microarray
Number of subjects: 106
Study 34128558 — intervention group
Group type: EXPERIMENTAL
Intervention: Euroline™ panel
Number of subjects: 106
Study 34128558 — intervention group
Group type: COMPARATOR
Intervention: All three assay systems
Number of subjects: 106
Study 34128812 — intervention group
Group type: EXPERIMENTAL
Intervention: Motivation and Skills Support app, used for 8 weeks
Number of subjects: 31
Study 34128818 — intervention group
Group type: EXPERIMENTAL
Intervention: Smart Choices 4 Teens (web-based intervention)
Number of subjects: 411
Study 34128818 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 411
Study 34128819 — intervention group
Group type: EXPERIMENTAL
Intervention: e-mhGAP-IG training
Number of subjects: 35
Study 34128819 — intervention group
Group type: COMPARATOR
Intervention: mhGAP-IG v2.0 training (control)
Number of subjects: 35
Study 34128911 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxford-12 Hip Score
Number of subjects: 500
Study 34128911 — intervention group
Group type: EXPERIMENTAL
Intervention: HOOS-12
Number of subjects: 500
Study 34128911 — intervention group
Group type: EXPERIMENTAL
Intervention: Equipercentile method
Number of subjects: 500
Study 34128911 — intervention group
Group type: EXPERIMENTAL
Intervention: Mapping methods (linear regression, tobit regression, quantile regression)
Number of subjects: 500
Study 34129158 — intervention group
Group type: EXPERIMENTAL
Intervention: Adipose tissue-derived mesenchymal stem/stromal cells (ADSC) infusion at a dosage of 1 million cells/kg of body weight via intravenous route.
Number of subjects: 31
Study 34129229 — intervention group
Group type: EXPERIMENTAL
Intervention: Decision Aid (DA)
Number of subjects: 0
Study 34129229 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-Provider Dyads
Number of subjects: 0
Study 34129237 — intervention group
Group type: EXPERIMENTAL
Intervention: SGLT2 inhibitors
Number of subjects: 42516
Study 34129237 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 42516
Study 34129363 — intervention group
Group type: EXPERIMENTAL
Intervention: Pulmonary artery pressure sensor implantation
Number of subjects: 1200
Study 34129366 — intervention group
Group type: EXPERIMENTAL
Intervention: Mechanical circulatory support (including vasopressors, intraaortic balloon pump, and extracorporeal membrane oxygenator)
Number of subjects: 1247
Study 34129366 — intervention group
Group type: EXPERIMENTAL
Intervention: Vasopressors (used in 1081 patients, 86.7%)
Number of subjects: 1247
Study 34129366 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraaortic balloon pump (used in 314 patients, 25.2%)
Number of subjects: 1247
Study 34129366 — intervention group
Group type: EXPERIMENTAL
Intervention: Extracorporeal membrane oxygenator (used in 496 patients, 39.8%)
Number of subjects: 1247
Study 34129486 — intervention group
Group type: EXPERIMENTAL
Intervention: Men
Number of subjects: 2798
Study 34129486 — intervention group
Group type: COMPARATOR
Intervention: Women
Number of subjects: 2798
Study 34129808 — intervention group
Group type: EXPERIMENTAL
Intervention: Corticosteroid treatment, specific dosage and duration not available
Number of subjects: 0
Study 34129808 — intervention group
Group type: COMPARATOR
Intervention: Control group, specific treatment not available
Number of subjects: 0
Study 34129837 — intervention group
Group type: COMPARATOR
Intervention: Healthy individuals
Number of subjects: 0
Study 34129837 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with periodontitis
Number of subjects: 0
Study 34130036 — intervention group
Group type: EXPERIMENTAL
Intervention: Pre-operative assessment of patients
Number of subjects: 44
Study 34130036 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-operative assessment of patients one year after surgery
Number of subjects: 44
Study 34130036 — intervention group
Group type: COMPARATOR
Intervention: Asymptomatic controls
Number of subjects: 44
Study 34130476 — intervention group
Group type: EXPERIMENTAL
Intervention: Conscious Sedation
Number of subjects: 0
Study 34130476 — intervention group
Group type: COMPARATOR
Intervention: General Anesthesia
Number of subjects: 0
Study 34130477 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor
Number of subjects: 0
Study 34130477 — intervention group
Group type: COMPARATOR
Intervention: Prasugrel
Number of subjects: 0
Study 34130554 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution-Focused Brief Therapy
Number of subjects: 30
Study 34130709 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral nutritional supplements (ONS) with nutritional counseling
Number of subjects: 0
Study 34130709 — intervention group
Group type: COMPARATOR
Intervention: Nutritional counseling alone
Number of subjects: 0
Study 34130731 — intervention group
Group type: EXPERIMENTAL
Intervention: Early combination (EC) therapy
Number of subjects: 537
Study 34130731 — intervention group
Group type: COMPARATOR
Intervention: Metformin monotherapy (MET)
Number of subjects: 537
Study 34130756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group received estimated maximum oxygen uptake (VO2 max) assessment.
Number of subjects: 1315
Study 34130756 — intervention group
Group type: EXPERIMENTAL
Intervention: Intervention group
Number of subjects: 1315
Study 34130756 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 1315
Study 34131041 — intervention group
Group type: EXPERIMENTAL
Intervention: Olaparib in combination with weekly carboplatin plus paclitaxel
Number of subjects: 35
Study 34131047 — intervention group
Group type: EXPERIMENTAL
Intervention: Youth with IGT or recently diagnosed type 2 diabetes (drug naive)
Number of subjects: 416
Study 34131047 — intervention group
Group type: COMPARATOR
Intervention: Adults with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes (drug naive)
Number of subjects: 416
Study 34131423 — intervention group
Group type: EXPERIMENTAL
Intervention: TAK-003 (tetravalent dengue vaccine)
Number of subjects: 400
Study 34131423 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 400
Study 34131623 — intervention group
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Number of subjects: 110
Study 34131821 — intervention group
Group type: EXPERIMENTAL
Intervention: HIPEC with gemcitabine administered at 1000 mg/m²
Number of subjects: 16
Study 34131914 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic seizure therapy (MST)
Number of subjects: 65
Study 34131914 — intervention group
Group type: COMPARATOR
Intervention: Electroconvulsive therapy (ECT)
Number of subjects: 65
Study 34132071 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous administration of high-dose selenium (2,000 μg/day)
Number of subjects: 68
Study 34132071 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified in the abstract)
Number of subjects: 68
Study 34132224 — intervention group
Group type: EXPERIMENTAL
Intervention: Isolated limb perfusion (ILP) with melphalan
Number of subjects: 60
Study 34132642 — intervention group
Group type: EXPERIMENTAL
Intervention: Directly Observed Therapy (DOT) via mobile health application carried out by community workers.
Number of subjects: 236
Study 34132642 — intervention group
Group type: EXPERIMENTAL
Intervention: Mobile health application for data collection and monitoring framework.
Number of subjects: 236
Study 34132698 — intervention group
Group type: EXPERIMENTAL
Intervention: Fenestrated-branched endovascular aortic repair (FB-EVAR)
Number of subjects: 430
Study 34133209 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline genotype-directed therapy
Number of subjects: 11947
Study 34133209 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline LP/P variant
Number of subjects: 11947
Study 34133209 — intervention group
Group type: EXPERIMENTAL
Intervention: Germline sequence analysis
Number of subjects: 11947
Study 34134507 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension during endovascular therapy in patients with no PComA
Number of subjects: 148
Study 34134507 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypotension during endovascular therapy in patients with PComA
Number of subjects: 148
Study 34134520 — intervention group
Group type: EXPERIMENTAL
Intervention: Niacin-statin combination therapy
Number of subjects: 244
Study 34134520 — intervention group
Group type: COMPARATOR
Intervention: Statin monotherapy
Number of subjects: 244
Study 34134744 — intervention group
Group type: EXPERIMENTAL
Intervention: Digitally supported care management programme
Number of subjects: 500
Study 34134744 — intervention group
Group type: COMPARATOR
Intervention: Usual care (wait-list control group)
Number of subjects: 500
Study 34134788 — intervention group
Group type: EXPERIMENTAL
Intervention: painTRAINER (internet-based pain coping skills training program)
Number of subjects: 60
Study 34134788 — intervention group
Group type: EXPERIMENTAL
Intervention: painTRAINER users (those who accessed the program)
Number of subjects: 60
Study 34134788 — intervention group
Group type: COMPARATOR
Intervention: wait list control group
Number of subjects: 60
Study 34134830 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Behavioral Therapy (CBGT)
Number of subjects: 58
Study 34134832 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory Support Treatment Provider Checklist
Number of subjects: 84
Study 34135022 — intervention group
Group type: EXPERIMENTAL
Intervention: Net endogenous acid production using food frequency questionnaires
Number of subjects: 642
Study 34135022 — intervention group
Group type: EXPERIMENTAL
Intervention: Net endogenous acid production using urinary excretion
Number of subjects: 642
Study 34135022 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher dietary acid load
Number of subjects: 642
Study 34135053 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient decision aid (PtDA) for 'timely' dementia diagnosis
Number of subjects: 0
Study 34135053 — intervention group
Group type: COMPARATOR
Intervention: Diagnostics as usual from their GPs (before group)
Number of subjects: 0
Study 34135471 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients (425 total)
Number of subjects: 1162
Study 34135471 — intervention group
Group type: COMPARATOR
Intervention: COVID-19 negative patients (737 total)
Number of subjects: 1162
Study 34135471 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall population (COVID-19 positive and negative)
Number of subjects: 1162
Study 34135471 — intervention group
Group type: EXPERIMENTAL
Intervention: COVID-19 positive patients
Number of subjects: 1162
Study 34135566 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravitreal injection guide (IIG)
Number of subjects: 200
Study 34135566 — intervention group
Group type: COMPARATOR
Intervention: Conventional dual blade speculum plus surgical caliper (DBS)
Number of subjects: 200
Study 34135690 — intervention group
Group type: EXPERIMENTAL
Intervention: Intracoronary thrombi aspirated from STEMI patients
Number of subjects: 33
Study 34135690 — intervention group
Group type: EXPERIMENTAL
Intervention: Inflammasome signaling pathway
Number of subjects: 33
Study 34135843 — intervention group
Group type: EXPERIMENTAL
Intervention: Repeated Mesenchymal Stem Cell Injections
Number of subjects: 0
Study 34135855 — intervention group
Group type: EXPERIMENTAL
Intervention: Elevated Cardiac Troponin I levels
Number of subjects: 0
Study 34135855 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34136023 — intervention group
Group type: COMPARATOR
Intervention: Standard Frontal View (SFV) colonoscopy
Number of subjects: 421
Study 34136023 — intervention group
Group type: EXPERIMENTAL
Intervention: Panoramic View Colonoscopy (PVC)
Number of subjects: 421
Study 34136023 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (SFV and PVC)
Number of subjects: 421
Study 34136337 — intervention group
Group type: EXPERIMENTAL
Intervention: Healthy Start/Départ Santé (HS/DS) intervention
Number of subjects: 39
Study 34136337 — intervention group
Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 39
Study 34136501 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide, a glucagon-like peptide-1 receptor agonist
Number of subjects: 0
Study 34136501 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 0
Study 34136542 — intervention group
Group type: EXPERIMENTAL
Intervention: Concomitant impairments of the left and right ventricular myocardial strain
Number of subjects: 0
Study 34136542 — intervention group
Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study 34136782 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer at doses ranging from 4.2 to 16.8 g twice daily
Number of subjects: 60
Study 34136782 — intervention group
Group type: EXPERIMENTAL
Intervention: Patiromer
Number of subjects: 60
Study 34136987 — intervention group
Group type: EXPERIMENTAL
Intervention: MT-8 h and MT-12 h formulations (120 mg)
Number of subjects: 0
Study 34136987 — intervention group
Group type: EXPERIMENTAL
Intervention: MT-12 h with a high-fat meal
Number of subjects: 0